Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Glioblastoma is the most common adult primary brain tumor and carries a dismal prognosis. Radiation is a standard first-line therapy, typically deployed following maximal safe surgical debulking, when possible, in combination with cytotoxic chemotherapy. For other systemic cancers, standard of care...
Main Authors: | Karishma R. Rajani, Lucas P. Carlstrom, Ian F. Parney, Aaron J. Johnson, Arthur E. Warrington, Terry C. Burns |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2018.00656/full |
Similar Items
-
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01) -
Immune Checkpoints and Innovative Therapies in Glioblastoma
by: Massimo Romani, et al.
Published: (2018-10-01) -
Cell-mediated immunotherapy: its role in cancer treatment
by: Deshpande, Janhavee
Published: (2017) -
PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2021-02-01)